VELOCITY: An Anthrax Vaccine Clinical Study

Summary

This study is designed to evaluate the lot consistency (using three consecutively manufactured lots), safety, and ability of the AV7909 anthrax vaccine to generate an immune response in healthy adults and compare the response to that induced by the currently licensed vaccine, BioThrax®, (Anthrax Vaccine Adsorbed; AVA) for post-exposure of anthrax disease.

Timeline

Start

2019-03-11

Primary completion

2020-08-06

Completion

2020-08-06

Publications

• Drobic B, Akintunde G, Kim J, Mirceta M, Beach M, Komlenovic V. Immunogenicity, safety, and lot consistency of the anthrax vaccine adsorbed, adjuvanted for post-exposure prophylaxis of anthrax in healthy adults: A phase 3, randomized, double-blind trial. Vaccine. 2026 Feb 6;72:128068. doi: 10.1016/j.vaccine.2025.128068. Epub 2025 Dec 15.

Drugs

Indications